This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

EDAP's Ablatherm-HIFU Receives Two Best Poster Awards At 2013 American Urological Association Annual Meeting

Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting Significant Interest in both HIFU and ESWL Technologies at EDAP Booth

LYON, France, May 14, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, highlighted its positive reception at the American Urological Association (AUA) 2013 Annual Meeting, held in San Diego on May 4-8, 2013. At the meeting, four scientific abstracts were presented regarding the outcomes for HIFU treatment of prostate cancer, and two regarding clinical use of the Sonolith lithotripter and its exclusive ultrasound Visio Track ® localization system. Two of the HIFU posters, #1208 and #1496, entitled The importance of biopsies in ablation therapies for prostate cancer: Start of salvage treatment for persistent positive biopsies after HIFU and HIFU treatment outcomes for localized prostate cancer from the first European centers, respectively, received Best Poster awards from the AUA.

On May 4, 2013, at the 28th Annual Meeting of the Engineering and Urology Society, held in conjunction with AUA, two posters highlighting HIFU were presented by Pr. Christian Chaussy of the University Regensburg, Germany. In addition, Pr. Chaussy gave an invited plenary session on long term results of HIFU for localized prostate cancer from his over 15 year experience with the procedure. 

Mr. Oczachowski, EDAP's Chief Executive Officer, said, "We are proud that two of our Ablatherm-HIFU posters received the best poster award during the AUA. This is clear academic recognition of HIFU as a valuable technology for treating prostate cancer and reflects positively on the high level of research supporting Ablatherm-HIFU. This is a key differentiation point for EDAP, and reinforces our established leadership in HIFU for the treatment of prostate cancer both from a technological and clinical standpoint."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs